brain in behaving animals (Jennings and Stuber, 2014) . One approach for monitoring circuit-specific activity dynamics is in vivo calcium imaging. During periods of increased neural activity, dynamic fluctuations in calcium levels correlate with events such as action potential generation, exocytosis of neurotransmitters, changes in synaptic plasticity, and gene transcription. Thus, monitoring calcium dynamics with genetically encoded calcium indicators, such as GCaMP6, can serve as a proxy for neural activity within defined neurocircuits (Chen et al, 2013) . Imaging of neural activity using calcium indicators has largely been accomplished with in vivo two-photon microscopy, which provides unprecedented cellular and subcellular spatial resolution; however, two-photon imaging must be performed in head-fixed animals, greatly limiting the assessment of naturalistic behavior (Svoboda and Yasuda, 2006) . To circumvent these limitations, new methods for visualizing and quantifying calciummediated fluorescent signals have been developed for use in freely moving animals.
Visualizing calcium transients in freely moving mice requires imaging devices that are small enough to fit on an animal's head and light enough to be carried by the animal. In the last few years, two such approaches have been developed: mini-epifluorescence microscopes used in conjunction with gradient index (GRIN) lens microendoscopes (Ziv et al, 2013) and fiber photometry (Cui et al, 2013; Gunaydin et al, 2014) (Figure 1 ). Mini-epifluorescence microscopes are ideal for measuring somatic calcium activity dynamics. Importantly, with this novel technology, the activity of hundreds of genetically and spatially defined neurons within a single animal can be repeatedly imaged, permitting the analysis of cellular network dynamics that orchestrate behavior as well as the transition to pathological disease states (Ziv et al, 2013) . In addition, both microendoscopic imaging and fiber photometry are capable of recording neural activity many millimeters deep within the brain. Fiber photometry utilizes optical fibers to detect bulk changes in calcium-mediated fluorescence in the soma (Cui et al, 2013) The human brain contains B100 billion anatomically and neurochemically heterogeneous neurons that form 100 trillion brain-wide connections giving rise to a complex network whose interconnected activity regulates behavior. A major challenge in neuroscience has been to decipher the discrete functional connectivity underlying normal or pathological behavior. Until recently, the primary methods for determining whole-brain functional activity as a consequence of discrete manipulation of specific cell populations was to study indirect markers such as c-Fos immunoreactivity in postmortem sections cut throughout the brain, or via in vivo blood oxygenation level-dependent measures using functional magnetic resonance imaging (fMRI), which requires experimental subjects to be fully immobilized. In an effort to overcome such limitations, we recently described the development and application of a new biobehavioral imaging methodology termed DREADD-assisted metabolic mapping (DREAMM) (Anderson et al, 2013; Michaelides et al, 2013) . DREAMM leverages the ability of designer receptor exclusively activated by designer drug (DREADD) chemogenetic technology, which enables remote, in vivo activation or inhibition of distinct sets of neurons that result in discrete perturbations in brain activity and behavior (Armbruster et al, 2007) , along with the unique capacity of positron emission tomography (PET) and [ 18 F]fluoro-2-deoxyglucose (FDG) for non-invasive, whole-brain, dynamic functional imaging in behaving humans and laboratory animals (Michaelides et al, 2013; Schulz et al, 2011; Villien et al, 2014) . DREAMM is thus the first technique that provides simultaneously quantitative, dynamic, whole-brain and regionally unbiased, cell type-specific functional circuit mapping captured during the awake, freely moving state.
DREAMM affords the unique flexibility of combining multiple strategies-molecular, viral, transgenic, and pharmacological (inert ligands that specifically target designer receptors)-to probe, in a mechanistic and unbiased manner, whole-brain functional networks and concomitant behaviors recruited upon stimulation or inhibition of a region-and neurochemically-specific cell type. In a typical DREAMM experiment, subjects are first exposed to a genetic engineering manipulation (eg, viral vector-based or transgenic model), resulting in regional or global expression of stimulatory or inhibitory DREADDs in targeted cell types. Subjects then undergo chemogenetic DREADD modulation by administering an inert ligand such as clozapine-N-oxide that specifically activates the DREADD and is combined with an FDG-PET behavioral imaging strategy. Either a 'snapshot' of wholebrain metabolic activity can be obtained during the DREADD-activated freely moving condition prior to imaging in a conventional PET scanner (Michaelides et al, 2013) or using headmounted mobile PET scanner technology whole-brain metabolic activity is simultaneously measured during behavioral monitoring (Schulz et al, 2011) .
DREAMM is currently the only imaging technology that relies on a direct and well-understood process of cellular function (ie, glucose utilization) as its functional output. Moreover, DREAMM is not limited to FDG, and can be implemented along with a variety of other PET probes (even in the same subject) that target alternative/complementary cellular processes such as neurotransmitter dynamics, receptor signaling, and enzymatic processes, thereby allowing investigation not only of the global long-range functional networks involved in cell type-specific behaviors, but also of the underlying neurochemistry. Another unique advantage of DREAMM is its potential to be performed completely non-invasively via the use of transgenic animal models with cell type-specific DREADD expression. Finally, the noninvasive nature of DREAMM when capturing whole-brain in vivo functional activity allows for longitudinal assessments in the same subject and for it to be combined with a variety of model-and disease-specific behavioral paradigms (Figure 1 ).
To date, DREAMM has been used to map novel whole-brain functional activity patterns to changes in motor behavior induced by remote modulation of neighboring, yet heterogeneous basal ganglia pathways (eg, ventral striatonigral and striatopallidal medium spiny neurons). This approach using viral vectors with engineered DREADD receptors under the control of promoters specifically expressed in different striatal pathways illustrated the distinct recruitment of discrete whole-brain functional anatomical signatures and motor behavior upon remote activation of each striatal network (Michaelides et al, 2013) . DREAMM has also been used to reverse translate the functional relevance of deficits in neuronal populations that have been virtually unstudied, such as periamygdaloid cortex prodynorphin neurons, in which disturbances were phenotypic of human heroin abusers and major depressive subjects. Novel insights obtained by DREAMM, in translational rodent models, revealed that remote inhibition of periamygdaloid prodynorphin neuronal activity resulted not only in negative affective behavioral regulation, but also in a marked, selective functional activation of the extended amygdala circuit, a brain network well linked to negative affect (Anderson et al, 2013) ( Figure 1 ). In addition to experimental rodents, DREAMM is now being used in nonhuman primates and has the potential to be implemented in the future in humans (pending advances in genetherapy safety/efficacy currently under development). The clinical relevance and translational therapeutics potential of DREAMM holds promise as an application for repeated, longitudinal, non-invasive assessment and monitoring of disease/therapy progression in patients undergoing DREADD-based neuromodulatory therapy. Furthermore, DREAMM would also have the capacity to be utilized alongside advanced cellular genetic engineering approaches such as combined DREADD and cell replacement therapeutics (Dell'Anno et al, 2014) to assess the efficient functional integration of such transplanted cells within neuronal networks.
In sum, DREAMM holds significant promise as a powerful, reverse-engineering strategy to visualize in vivo-specific neuronal ensemble networks associated with normal and pathologic behavior and to thus enhance knowledge about distinct neuronal circuits relevant to neuropsychiatric disorders. : 192-199. Neuropsychopharmacology Reviews (2015) 40, 239-241; doi:10.1038 /npp.2014 More than a Gut Feeling: the Microbiota Regulates Neurodevelopment and Behavior
The realization of the importance of the gut microbiota in health and disease has been one of the most exciting areas in biomedical research over the past 5 years. We are teeming with microrganisms in and on our body, having 4150 times more microbial genes (the microbiome) than mammalian genes. Studies are revealing how variations in the composition of the gut microbiota influence all aspects of physiology, including brain function and even behavior. In terms of neuroscience and psychiatric disease the field is still very much in its infancy, but evidence is accumulating that it has a key role. Factors that shape the bacterial landscape include being born by Caesarian delivery, not being breastfed, environment, gestational age, host genetics, exposure to infections (both maternal and infant), and antibiotic usage. Moreover, stress, especially that in early life and prenatally, can have marked effects on microbiota composition (Borre et al, 2014) . A variety of strategies have been used to investigate the role of this socalled microbiota-gut-brain axis in health and disease. Germ-free mice (mice that never have been exposed to any bacteria) have been used to show that microbiota is crucial for hypothalamic-pituitary-adrenal axis function. Moreover, these mice have widespread neurodevelopmental changes in the brain, including alterations in monoaminergic neurotransmission and behavioral changes in anxiety (Foster and McVey Neufeld, 2013) . More recently, we have shown that these mice also exhibit autismlike traits, such as deficits in sociability, social cognition, and increased repetitive behaviors (Desbonnet et al, 2014) . Interestingly, as in autism and other neurodevelopmental disorders, these effects are much more pronounced in males than females. Moreover, studies in germ-free mice can be expanded to enable research on the 'humanization' of the gut microbiota, that is, transplanting faecal microbiota from specific human conditions or from animal models. Indeed, it has been shown that behavioral traits can be transplanted between strains of mice (Collins et al, 2013) .
Administration of various potential probiotic strains in rodents or humans has also been shown to have beneficial effects in rodents. Major strain and species differences occur in terms of their 'psychobiotic' effects. Studies have shown that some Bifidobacteria and Lactobacilli species as well as Bacteroides fragilis can have positive effects on anxiety, depression, cognition, and autism-related behaviors (Hsiao et al, 2013) . Prebiotics, nondigestible food ingredients that promotes the growth of beneficial gut microorganisms, are also being shown to affect brain BDNF levels. Human studies of prebiotics and probiotics have lagged behind to date, although there is interesting neuroimaging studies emerging clearly showing that such bacterial-based dietary interventions can affect brain function.
